---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028761"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:53:16.782116+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q3 net sales up 25.9% to $137.1M, but cuts full-year 2022 guidance sharply

## Summary
- Q3 net sales $137.1M (+25.9% YoY); net income $3.2M vs net loss $2.3M prior year.
- Adjusted EBITDA $22.7M (+$1.3M YoY); Non-GAAP EPS $0.08, down from $0.19 prior year.
- Full-year 2022 guidance lowered: net sales $527-532M, Adj. EBITDA $75-79M, Non-GAAP EPS $0.20-0.25.
- Debt increased to $424.4M from $357.7M at Dec 2021; cash $34.4M.
- CEO highlights recent CartiHeal acquisition to enter large cartilage replacement market.

## SEC filing metadata
- accession: 0001628280-22-028761
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828022028761/0001628280-22-028761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828022028761/bvs-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028761
- JSON: https://secwatch.observer/filing/0001628280-22-028761.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028761.txt

## Key facts
- Earnings Releases
  Bioventus Inc. reported three and nine months ended October 1, 2022 results: revenue $137.1 million, net income $3.2 million, EPS $0.03.
  - Period: three and nine months ended October 1, 2022
  - Revenue: $137.1 million
  - Net income: $3.2 million
  - EPS: $0.03
  - Result: reported results
  source text: in innovations for active healing, today reported financial results for the three and nine months ended October 1, 2022. Q3 Financial Summary & Recent Highlights: • Net Sales of $137.1 million, up $28.2 million, or 25.9%, year-over-year as reported (26.8% constant currency*) and 7.3% organically* (8.1% constant currency*) • Net Income of $3.2 million, compared to Net
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828022028761/0001628280-22-028761-index.htm
- Earnings Releases
  Bioventus Inc. reported twelve months ending December 31, 2022 results: revenue $527 million to $532 million, EPS $0.20 to $0.25. Guidance lowered.
  - Period: twelve months ending December 31, 2022
  - Revenue: $527 million to $532 million
  - EPS: $0.20 to $0.25
  - Guidance: lowered
  - Result: guidance update
  source text: Updated Full Year 2022 Financial Guidance: For the twelve months ending December 31, 2022, the Company now expects: • Net sales of $527 million to $532 million, representing year-over-year growth of approximately 22% to 23%, representing an update to the prior guidance of $547.5 million to $562.5 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828022028761/0001628280-22-028761-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.